Physician profile
Tamara Kermani
NPI 1174887608
$1,351.93
in general payments reported to CMS, 2019-2025
23 companies · $155 in 2025
The $155 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $74.61 · 2020: $56.56 · 2021: $331 · 2022: $381 · 2023: $316 · 2024: $37.30 · 2025: $155.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $507.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $134.70 | 2020-2023 | Rybelsus, Ozempic |
| Pfizer INC. | $110.70 | 2019-2023 | |
| Xeris Pharmaceuticals, INC. | $97.09 | 2022-2023 | Gvoke Hypopen |
| Bayer Healthcare Pharmaceuticals INC. | $96.73 | 2022-2025 | |
| Amgen INC. | $96.02 | 2021-2023 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $88.69 | 2021-2025 | Penmenvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $88.40 | 2019-2024 | Mounjaro, Zepbound |
| Astellas Pharma US INC | $72.82 | 2020-2025 | Veozah |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.58 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $61.99 | 2021 | |
| Radius Health, INC. | $61.23 | 2024-2025 | |
| Abbott Laboratories | $57.81 | 2021-2023 | Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $52.06 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $44.54 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $43.47 | 2022-2023 | Farxiga |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $35.19 | 2025 | Slynd |
| Amarin Pharma, INC. | $29.87 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $29.39 | 2021 | |
| Supernus Pharmaceuticals, INC. | $21.40 | 2022 | |
| Sumitomo Pharma America, INC. | $19.61 | 2023 | Gemtesa |
| Ironshore Pharmaceuticals INC. | $13.91 | 2019 | |
| Sanofi Pasteur INC. | $13.87 | 2019 | |
| Horizon Therapeutics Plc | $12.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Kermani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.